TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29710212

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (1.5, 3.0, or 9.0 U per 0.1 mL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (9.0 U)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 9
Study: 26808629

Group type: EXPERIMENTAL
Intervention: Intervention group (algorithm to prevent cerebral desaturation)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study: 24315720

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 85
Study: 22137565

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 20646412

Group type: EXPERIMENTAL
Intervention: Zhibitai (480 mg orally twice a day)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg orally once daily)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Zhibitai and Atorvastatin (both groups)
Number of subjects: 169
Study: 17191187

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% added to travoprost 0.004%
Number of subjects: 192

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% added to travoprost 0.004%
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 192

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 192
Study: 14586167

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg and 600 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg)
Number of subjects: 24
Study: 10889930

Group type: EXPERIMENTAL
Intervention: Sucralfate (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 44
Study: 9280995

Group type: EXPERIMENTAL
Intervention: Methadone (5 mg methadone/5 ml saline) applied to the dura before the end of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 40
Study: 1581081

Group type: EXPERIMENTAL
Intervention: CarboMedics prosthesis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Björk‐Shiley monostrut prosthesis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: StJude Medical prosthesis
Number of subjects: 141
Study: 2997315

Group type: EXPERIMENTAL
Intervention: Soybean polysaccharide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 31809403

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (10, 20, and 40 mg administered over 2 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-blind placebo treatment
Number of subjects: 0
Study: 29486598

Group type: EXPERIMENTAL
Intervention: New X-ray imaging platform (AlluraClarity) with reduced dose settings
Number of subjects: 41
Study: 26644222

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with milk protein base (54 g/day)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with soya protein base (54 g/day)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified corn-soya blend (71 g/day)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 213
Study: 24445981

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (40 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chloral hydrate and hydroxyzine (40 mg/kg + 2 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chloral hydrate and promethazine (40 mg/kg + 1 mg/kg)
Number of subjects: 90
Study: 22259065

Group type: EXPERIMENTAL
Intervention: Postnatal 17β-estradiol (E2) and progesterone (P) replacement
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 61
Study: 19926685

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 513
Study: 17499427

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 200
Study: 17348236

Group type: EXPERIMENTAL
Intervention: Polyhedron method
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bisection method
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 43
Study: 12637460

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 60 mg/m(2)
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 75 mg/m(2)
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 90 mg/m(2)
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) + Doxorubicin (A) + Paclitaxel (175 mg/m(2))
Number of subjects: 3121

Group type: COMPARATOR
Intervention: Cyclophosphamide (C) + Doxorubicin (A)
Number of subjects: 3121
Study: 10758778

Group type: EXPERIMENTAL
Intervention: Artichoke dry extract (1,800 mg per day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 8836707

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg a day for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1316058

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Amoxicillin 500 mg every 8 hours
Number of subjects: 157
Study: 4077578

Group type: EXPERIMENTAL
Intervention: Multivitamin and iron supplement (twice weekly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29566406

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2394

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (tangential clamping)
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (clampless device)
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (no aortic manipulation)
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Aggregate analysis (off-pump CABG)
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Aggregate analysis (on-pump CABG)
Number of subjects: 2394
Study: 27928441

Group type: EXPERIMENTAL
Intervention: Selected exercise program for 24 sessions, 90 minutes per session
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 24866839

Group type: EXPERIMENTAL
Intervention: PARSS intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21900849

Group type: EXPERIMENTAL
Intervention: Flaxseed bar (410 mg of lignans) for 6 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo bar for 6 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Flaxseed bar and Placebo bar
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo bar
Number of subjects: 188
Study: 20441245

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 600 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 1000 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 1200 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 1300 microg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Naltrexone 50 mg
Number of subjects: 120
Study: 18827289

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone and Perphenazine
Number of subjects: 0
Study: 16240707

Group type: EXPERIMENTAL
Intervention: Winex (100 mg/5 ml) suspension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Suprax (100 mg/5 ml) suspension
Number of subjects: 24
Study: 11910260

Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 10331850

Group type: EXPERIMENTAL
Intervention: Simulated mobile phone signal at 915 MHz (1 W mean power)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Digital simulation of mobile phone signal at 915 MHz
Number of subjects: 36

Group type: COMPARATOR
Intervention: No power (control group)
Number of subjects: 36
Study: 8576506

Group type: EXPERIMENTAL
Intervention: Self-medication program (SMP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 107
Study: 1672895

Group type: EXPERIMENTAL
Intervention: Generic carbamazepine (100 and 200 mg tablets)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Proprietary carbamazepine (Tegretol)
Number of subjects: 12
Study: 7019268

Group type: EXPERIMENTAL
Intervention: Hibitane Dental (ICI)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Plak-Out (Hawe)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.2% aqueous solution of chlorhexidine gluconate
Number of subjects: 13
Study: 31194598

Group type: EXPERIMENTAL
Intervention: Six Dried Plums (∼42 g) per day for 2 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Two Dried Plums (∼14 g) per day for 2 weeks
Number of subjects: 27
Study: 28763737

Group type: EXPERIMENTAL
Intervention: Attentional avoidance
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attentional focusing
Number of subjects: 44
Study: 26073878

Group type: EXPERIMENTAL
Intervention: Glucocorticoid users
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study: 23224687

Group type: EXPERIMENTAL
Intervention: Resveratrol-containing grape extract (8 mg resveratrol)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional grape extract
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21563022

Group type: EXPERIMENTAL
Intervention: Response training (mastication task in response to a visual signal)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no response training)
Number of subjects: 14
Study: 18474729

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (220 mg twice daily)
Number of subjects: 2117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2117
Study: 17000818

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham intrathecal injection (placebo)
Number of subjects: 40
Study: 12562833

Group type: EXPERIMENTAL
Intervention: FAT (50 g/m2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLUCOSE (37.5 g/m2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MIXED test (combination of FAT and GLUCOSE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: WATER
Number of subjects: 8
Study: 11878358

Group type: EXPERIMENTAL
Intervention: Intensive dissemination (mail-out plus personal contact with midwifery facilitators)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Simple dissemination (mail-out)
Number of subjects: 23
Study: 9013365

Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin) at dosage levels from 1 mg/m2/day to 13 mg/m2/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1392995

Group type: EXPERIMENTAL
Intervention: Omeprazole for four weeks plus bismuth 120 mg, tetracycline 500 mg, and metronidazole 400 mg (all four times a day) for the first week (n = 78)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Omeprazole alone for four weeks (n = 77)
Number of subjects: 155
Study: 2865417

Group type: EXPERIMENTAL
Intervention: Corticosteroids/calcitonin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mithramycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aminohydroxypropylidene diphosphonate (APD)
Number of subjects: 39
Study: 31029558

Group type: EXPERIMENTAL
Intervention: Low plasma IL-8 levels (Trajectory group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Trajectory group 2 (higher IL-8 levels)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Trajectory group 3 (highest IL-8 levels)
Number of subjects: 58
Study: 29127137

Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption (ATI)
Number of subjects: 0
Study: 26847108

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) and methotrexate (MTX)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methotrexate (MTX) with additional synthetic disease modifying anti‐rheumatic drugs (sDMARDs)
Number of subjects: 120
Study: 25677175

Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention (TSI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Uterine Artery Doppler Screening (UADS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Face to face midwifery visits
Number of subjects: 45
Study: 23447917

Group type: EXPERIMENTAL
Intervention: 30 mg Pycnogenol twice daily for 3 months
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 21904014

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived cells (5 cc)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Whole blood (5 cc)
Number of subjects: 48
Study: 18498663

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole or 20 mg rabeprazole for 8 days (treatment group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not applicable (control group measured as integrated acidity)
Number of subjects: 106
Study: 17052624

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plain
Number of subjects: 102

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80.000 epinephrine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-power laser irradiation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac
Number of subjects: 102

Group type: COMPARATOR
Intervention: Regular postoperative recommendations
Number of subjects: 102
Study: 12713711

Group type: EXPERIMENTAL
Intervention: Low-dose acetazolamide (125 mg BID)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 11498723

Group type: EXPERIMENTAL
Intervention: 100 mg NF
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 200 mg NF
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9755351

Group type: EXPERIMENTAL
Intervention: Videotapes (three experimental types)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 258
Study: 8141572

Group type: EXPERIMENTAL
Intervention: Meropenem 1-g intravenous intermittent infusions every 8 h
Number of subjects: 12
Study: 3411648

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine cream
Number of subjects: 0
Study: 29782648

Group type: EXPERIMENTAL
Intervention: Topical treatments for AK
Number of subjects: 109
Study: 28501063

Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 0
Study: 25315022

Group type: COMPARATOR
Intervention: Placebo treatment with Unna's boot
Number of subjects: 17
Study: 23370085

Group type: EXPERIMENTAL
Intervention: Real tDCS (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS (n=20)
Number of subjects: 40
Study: 21983154

Group type: EXPERIMENTAL
Intervention: Quadrivalent live attenuated influenza vaccine (Q/LAIV), n=1200
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Trivalent live attenuated influenza vaccine (T/LAIV), n=600
Number of subjects: 1800
Study: 17928802

Group type: EXPERIMENTAL
Intervention: 20 mg iron daily for 8 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 40 mg iron daily for 8 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 80 mg iron daily for 8 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: 20 mg iron group
Number of subjects: 180

Group type: COMPARATOR
Intervention: 40 mg iron group
Number of subjects: 180
Study: 17120694

Group type: EXPERIMENTAL
Intervention: Affective pictures with unpleasant, neutral, and pleasant contents
Number of subjects: 61

Group type: COMPARATOR
Intervention: Affective pictures of two sizes (120 x 90 cm and 52 x 42 cm)
Number of subjects: 61
Study: 15646910

Group type: COMPARATOR
Intervention: 0.5 mg/kg of oral midazolam (MDZ) 20 minutes prior to treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg oral midazolam (MDZ) with 3.7 mg/kg of hydroxyzine (MDZH) 30 minutes before treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of hydroxyzine (3.7 mg/kg) with MDZ (0.3 mg/kg)
Number of subjects: 28
Study: 11349929

Group type: EXPERIMENTAL
Intervention: Noncycloplegic near retinoscopy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cycloplegia with tropicamide 1%
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cycloplegia with cyclopentolate 1%
Number of subjects: 29
Study: 9146780

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 96
Study: 7993154

Group type: EXPERIMENTAL
Intervention: Empiric fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial EGD and fluconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial EGD and fluconazole compared to empiric fluconazole
Number of subjects: 0
Study: 31772401

Group type: EXPERIMENTAL
Intervention: Ultrasound group ('B') - Combined Spinal Epidural Anaesthesia (CSEA) after preprocedural lumbar ultrasound scan
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group ('A') - CSEA given by blind conventional technique
Number of subjects: 210
Study: 28796278

Group type: EXPERIMENTAL
Intervention: PNF stretching (hold-relax-with agonist contraction)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 15

Group type: COMPARATOR
Intervention: No stretching
Number of subjects: 15
Study: 27025297

Group type: EXPERIMENTAL
Intervention: Individualized household allergen reduction
Number of subjects: 247

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 247
Study: 24773573

Group type: EXPERIMENTAL
Intervention: Personalized feedback with motivational interviewing
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Personalized feedback without motivational interviewing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 68
Study: 22057205

Group type: EXPERIMENTAL
Intervention: Stereotaxic location puncture and dilation procedures
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional procedure
Number of subjects: 400
Study: 20482275

Group type: EXPERIMENTAL
Intervention: High-maize 260 resistant starch (12 g added RS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control bread (no added RS)
Number of subjects: 15
Study: 18391573

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 193
Study: 16368449

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 2297

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 2297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297
Study: 12357148

Group type: EXPERIMENTAL
Intervention: Heparin concentration‐based anticoagulation management (Hepcon HMS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Activated clotting time‐based heparin management
Number of subjects: 200
Study: 10348536

Group type: EXPERIMENTAL
Intervention: trapidil (400 mg/d) + ticlopidine (500 mg) for the first month
Number of subjects: 118

Group type: COMPARATOR
Intervention: aspirin (325 mg/d) + ticlopidine (500 mg) for the first month
Number of subjects: 118
Study: 7806173

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/Kg intravenously)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 1719734

Group type: EXPERIMENTAL
Intervention: Low-molecular dextran 40
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 40/0.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaCl-infusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheologically effective substances (low-molecular dextran 40 and 6% hydroxyethyl starch 40/0.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zero or next to zero therapy
Number of subjects: 0
Study: 6176354

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with MFC plus OK‐432 (group A)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Immunotherapy with OK‐432 alone (group B)
Number of subjects: 83
Study: 31310775

Group type: EXPERIMENTAL
Intervention: 1 mcg/kg intravenous ghrelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mcg/kg intravenous ghrelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29888729

Group type: EXPERIMENTAL
Intervention: Audiovisual presentations (Group V, n = 33)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Auditory presentations (Group A, n = 33)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (Group C, n = 33)
Number of subjects: 99
Study: 26364889

Group type: EXPERIMENTAL
Intervention: Otoscopy training using OtoSim simulator; 1-hour teaching session
Number of subjects: 57
Study: 25049338

Group type: EXPERIMENTAL
Intervention: 6-session intervention based on trauma-focused cognitive behavior therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: 1-session active comparison intervention (education about NICU and parenting)
Number of subjects: 105
Study: 21942377

Group type: EXPERIMENTAL
Intervention: Reappraisal condition (participants instructed to think about their physiological arousal as functional and adaptive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention reorientation (control condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instructions (control condition)
Number of subjects: 0